Question

138886 | Pre-Survey | Achieving Improved Ocular Surface Health in Dry Eye Disease: A Pharmacy-Focused Review at the Forefront of a New Treatment Era (Pharmacy Technicians)

1.
Which of the following BEST illustrates the functional and quality-of-life (QOL) burden of dry eye disease (DED)?

Most patients report only mild discomfort with no impact on daily activities

DED symptoms are predictable and consistent throughout the day for all patients

About 60% and 40% of patients report reduced QOL and work efficiency, respectively

The burden of DED is minimal compared with other chronic diseases such as angina

Unsure

2.
When learning about DED, what does the term “phenotype” mean?

A classification that distinguishes between aqueous-deficient, evaporative, or mixed DED

A type of questionnaire used to measure vision-related QOL and tear production

A laboratory test that measures ocular surface inflammation to diagnose DED

A preservative that may cause ocular surface toxicity and should be avoided

Unsure

3.
Why is the lacrimal functional unit highlighted in DED as a therapeutic target?

It reflects the inflammatory cytokines driving ocular surface damage

It integrates glands, tear film, and neural pathways essential for tear homeostasis

It is the most common site of conjunctival redness and irritation

It determines the mechanical blinking rate in patients with DED

Unsure

4.
Which statement BEST reflects the treatment of DED in the United States (US)?

Most patients with DED use prescription therapies long-term without discontinuation

Fewer than 10% of diagnosed patients use long-term prescription therapy

Patients with DED rarely use over-the-counter (OTC) artificial tears to control symptoms

DED is typically cured after a short course of topical corticosteroid therapy

Unsure

5.
Which of the following products is LEAST likely to aggravate DED due to meibomian gland dysfunction?

Preservative-containing “redness-relief” drops with vasoconstrictors

High-viscosity ointment for daytime use to maximize lubrication

Lipid-containing, preservative-free artificial tears used regularly

Astringent-containing tears to clear mucus from the ocular surface

Unsure

6.
According to the American Academy of Ophthalmology (AAO)’s stepwise treatment algorithm, which of the following is recommended as a first-line measure for all patients with DED?

Varenicline nasal spray and lifestyle modification

Punctal occlusion and patient education

Topical corticosteroids and artificial tears

Artificial tears and patient education

Unsure

7.
A patient tells a pharmacy technician that her artificial tears are not helping her dry eye symptoms and asks what she should do next. What is the most appropriate action for the technician?

Offer to refill her cyclosporine eye drops early to double-up her dose

Suggest adding OTC corticosteroid eye drops for a few weeks

Refer the patient to the pharmacist for further counseling

Advise the patient that she may have Sjogren’s disease and to call her doctor

Unsure

8.
What is the mechanism of action of transient receptor potential melastatin 8 (TRPM8) agonists in DED therapy?

Blocking calcineurin to reduce T-cell activation

Antagonizing LFA-1 to prevent inflammatory cytokine release

Stabilizing the lipid layer to reduce tear evaporation

Stimulating cold-sensing corneal receptors to enhance tear production

Unsure

9.
In the phase 3 COMET trials, which outcome best reflects the clinical benefit of acoltremon in patients with DED?

No difference from vehicle in Schirmer scores through 90 days

Significant tear production increases within 14 days, sustained through 90 days

Improvements in ocular redness, with no impact on patient-reported outcomes

Rapid tear production improvement requiring concurrent corticosteroid therapy

Unsure

10.
A patient prescribed acoltremon asks if there is any information available about this new product. What is the most appropriate response?

Provide detailed counseling about dosing and adverse effects to ease her concerns

Refer her to the pharmacist for counseling or to the product’s patient website

Recommend that she check social media for other users’ experiences

Suggest discontinuing acoltremon immediately if adverse effects occur

Unsure

11.
How confident are you in your ability to manage patients with dry eye disease?

Not at all confident

Somewhat confident

Confident

Highly confident
2025 Credits Earned:
0.00
View Your State Requirements FL Approved Courses - Click Here

FAQ
About Us
Contact Us
Group Purchases
Subscribe to Emails
Privacy Policy
Cookie Policy
Terms and Conditions
© 1997 - 2025 Postgraduate Healthcare Education, LLC (PHE). All rights reserved. Reproduction in whole or in part without permission is prohibited.
LinkedIn Twitter

Answer 1

Here are the best answers with brief explanations:

1) About 60% and 40% of patients report reduced QOL and work efficiency, respectively
- DED often causes substantial functional and QOL burden and reduced work productivity.

2) A classification that distinguishes between aqueous‑deficient, evaporative, or mixed DED
- “Phenotype” refers to clinical subtypes of DED.

3) It integrates glands, tear film, and neural pathways essential for tear homeostasis
- The lacrimal functional unit coordinates tear production and ocular surface health.

4) Fewer than 10% of diagnosed patients use long-term prescription therapy
- Most patients rely on OTC measures; long‑term Rx use is relatively uncommon.

5) Lipid-containing, preservative-free artificial tears used regularly
- Lipid-containing PF tears help restore the lipid layer and are least likely to worsen MGD.

6) Artificial tears and patient education
- AAO recommends conservative measures (lubrication + education) as first-line for all patients.

7) Refer the patient to the pharmacist for further counseling
- A technician should escalate to the pharmacist for assessment and treatment recommendations.

8) Stimulating cold-sensing corneal receptors to enhance tear production
- TRPM8 agonists activate cold receptors to increase tear secretion.

9) Significant tear production increases within 14 days, sustained through 90 days
- COMET showed rapid and sustained increases in tear production with acoltremon.

10) Refer her to the pharmacist for counseling or to the product’s patient website
- Pharmacist counseling or official product information is the appropriate next step for a new Rx.

11) (Subjective) Please select the option that best reflects your confidence: Not at all / Somewhat / Confident / Highly confident

If you want, I can expand any explanation or provide references.